Pharmaceutical

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).

Jan 9, 2024 - 18:00
EC approves Pfizer’s Talzenna combo for prostate cancer treatment
The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).
Read the original article

Tags:

Previous Article

BIOS Health to launch precision medicine centre in California, US

Next Article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis signs agreement for Legend Biotech’s CAR-T therapies

Novartis signs agreement for Legend Biotech’s CAR-T the...

Nov 14, 2023

Trans health care, already under attack, faces new obstacle with end of Covid public health emergency

Trans health care, already under attack, faces new obst...

Apr 1, 2023

STAT+: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS

STAT+: Under protest, FDA to convene advisory panel to ...

Mar 28, 2023